The nuclear retinoic acid (RA) receptor alpha (RARα) is a transcriptional transregulator that controls the expression of specific gene subsets through binding at response elements and dynamic interactions with coregulators, which are coordinated by the ligand. Here, we highlighted a novel paradigm in which the transcription of RARα-target genes is controlled by phosphorylation cascades initiated by the rapid RA activation of the p38MAPK/MSK1 pathway. We demonstrate that MSK1 phosphorylates RARα at S369 located in the Ligand Binding Domain, allowing the binding of TFIIH and thereby phosphorylation of the Nterminal domain at S77 by cdk7/cyclin H. MSK1 also phosphorylates Histone H3 at S10.
INTRODUCTION
Nuclear Retinoic Acid (RA) receptors (RARs) consist of three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3)
1-3 which function as ligand-dependent transcriptional regulators heterodimerized with Retinoid X Receptors (RXRs). The basic mechanism for transcriptional regulation by RARs relies on binding to specific response elements (RAREs) located in the promoters of target genes and on ligand-induced structural rearrangements in the Ligand
Binding Domain (LBD) that direct the association/dissociation of coregulator complexes with different enzymatic activities including Histone Acetyltransferases/Deacetylases, Histone
Methyltransferases/Demethylases, Kinases/Phosphatases, Ubiquitin-ligases/deubiquitinases or DNA-dependent ATPases [4] [5] [6] . The exchanges between coregulatory complexes and RARs are dynamic and coordinated 7, 8 . In fine, they cooperate to alter the chromatin structure surrounding the promoter of target genes, paving the way for the recruitment of the transcription machinery including RNA Polymerase II and the General Transcription Factors 9 .
A concept that developed over the last several years is that RARs are subject to phosphorylations 10 ,which play an important and ever-growing role in the transcription of RAtarget genes [11] [12] [13] [14] . However, the process appeared to be complex and nothing is known about the upstream kinases that govern RAR phosphorylation in response to RA and how RARs phosphorylation impacts the transcription of target genes. Because p38MAPK is activated in response to RA [15] [16] [17] , we explored whether there is a connection between this kinase signaling pathway, RARα phosphorylation and the induction of RARα-target genes.
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RESULTS

RA activates p38MAPK leading to MSK1 activation.
In Mouse Embryo Fibroblasts (MEF), p38MAPK was activated within minutes following RA treatment. This activation was transient as it peaked at 15 min and was reversed at 60 min (Fig. 1a) . P38MAPK was similarly activated by a synthetic RARα agonist but not by RARγ and RARβ agonists nor by RARα antagonists (Fig. 1a) . P38MAPK activation was not observed in MEF knockout for the three RARs, MEF (RARα,β,γ) -/-18,19 , but was restored upon reexpression of RARαWT (Fig. 1b) , indicating that activation of p38MAPK requires liganded RARα. P38MAPK was also rapidly activated in human breast cancer cell lines, such as MCF7 cells, but not in SKBR3 cells (Fig. 1c) .
Downstream of p38MAPK, there is MSK1 20 which contributes to the regulation of the expression of several genes 21, 22 . After RA treatment of MCF7 cells and MEFs, there was an increase in the activated, phosphorylated form of MSK1 which paralleled the increase in phosphorylated p38MAPK (Fig. 1d ,e). Activation of MSK1 was inhibited upon knockdown of p38MAPK with specific siRNA (Fig. 1f) or by SB203580, a selective inhibitor of p38MAPK (data not shown), corroborating that activation of MSK1 occurs downstream of p38MAPK in RA signaling. Accordingly, MSK1 was not activated in SKBR3 cells, which are defective in RA induction of p38MAPK (Fig.1e ). Other signaling pathways that have been shown to participate in hormone signaling such as Erks and the cAMP/PKA pathways were not activated after RA treatment (data not shown).
RA-activated MSK1 phosphorylates RARα at S369, in vivo.
Then we wondered if the rapid and transient RA activation of the p38MAPK/MSK1
pathway was associated with a change in the phosphorylation status of RARα. The RARα protein can be phosphorylated at two serine residues, S77 and S369 located in the N-and C-22/07/08 5 terminal domains respectively 10 ( Fig. 2a) . S77 is phosphorylated by the CAK subcomplex of the general transcription factor TFIIH either in vitro (Fig. 2b) or in vivo 11, 23 . However the kinase that phosphorylates in vivo S369, in response to RA, has not yet been identified. S369
belongs to an Arg-Lys rich motif which corresponds to a consensus phosphorylation site for several kinases including MSK1 (Fig. 2a) . In in vitro phosphorylation experiments, active recombinant MSK1 phosphorylated purified bacterially expressed RARα at S369 (and not at S77), as assessed by immunoblotting with antibodies recognizing specifically RARα phosphorylated at these residues. (Fig. 2b) .
We also analyzed the in vivo phosphorylation of endogenous RARα in MCF7 cells, after PhosphoProtein affinity purification. The amount of phosphorylated RARα markedky increased at 5-30 min and decreased 60 min after RA treatment (Fig. 2c) , in parallel to the activation of p38MAPK/MSK1. This increase in RARα phosphorylation concerned S369 (Fig. 2d) . It was inhibited upon knockdown of MSK1 (Fig. 2e ) and did not occur in SKBR3 cells, which are defective in MSK1 activation (Fig. 2d) , highlighting the importance of the initial RA activation of MSK1 in RARα phosphorylation at S369.
In vivo, S369 phosphorylation directs RARα interaction with TFIIH and thereby
S77 phosphorylation.
RARα was also rapidly phosphorylated at S77 after RA addition (Fig. 2d) .
Unexpectedly, though S77 was not a target for MSK1, phosphorylation of this residue was inhibited by SB203580 and by siRNA against MSK1 ( Fig. 2e and data not shown). Therefore, we wondered if phosphorylation of S77 might be controled by that of S369.
MEF expressing RARα either WT, S77A or S369A, as the sole RA-dependent transcriptional activator in a (RARα,β,γ) -/-background were generated and compared for RARα phosphorylation at 5 min intervals following RA addition. In each rescue cell line, 22/07/08 6 MEF(RARαWT), MEF(RARαS369A) and MEF(RARαS77A), the RARα protein was expressed at similar amounts ( Fig. 2f ) and the p38MAPK/MSK1 pathway was similarly activated in response to RA (Supplemental information, Fig. S1a ). In RA-treated MEF(RARαWT), the amount of RARα phosphorylated at S369 and S77 also increased rapidly at 5-15 min (Fig. 2g, lanes 1-4) , and was abrogated upon MSK1 knockdown (data not shown). In MEF(RARαS369A) (Fig. 2g , lanes 5-8) and MEF(RARαS77A) (Fig. 2g, Fig.S1b ).
The integrity of the p38MAPK/MSK1 pathway and of the RARα phosphorylation sites are required for the RA induction of RARα-target genes.
We next asked whether activation of MSK1 is significant for the activation of RARα-target genes. In MCF7 cells and MEFs, RA treatment enhances transcription of the Cyp26A1 gene which is the paradigm of the RA-target genes, as assessed by qRT-PCR (Fig. 3a,b) . No activation of Cyp26A1 was observed upon knockdown of MSK1 (Fig. 3c,d ) or in SKBR3 cells which are refractory to MSK1 activation (Fig. 3b) highlighting the significance of MSK1 activation for RA induction of RARα-target genes.
The RA-induced activation of CYP26A1 was also abrogated in MEFs in which all
RARs have been deleted, but was reestablished upon reintroduction of RARαWT (Fig. 3a) .
However, the RA response was not restored upon reintroduction of the RARαS369A and RARαS77A mutants (Fig.3a) , indicating that phosphorylation of S77 and S369 is also required for RARα-mediated transcription.
Upon RA treatment, RARα is recruited with TFIIH to the promoter of the Cyp26A1 gene.
Next we used chromatin immunoprecipitation (ChIP) experiments to gain mechanistic insight into the role of MSK1 activation and/or RARα phosphorylation in the activation of Cyp26A1 expression. The CYP26A1 gene promoter contains two functional DR5 RAREs, a 22/07/08 8 proximal one (R1) and a more distal one (R2) (Fig. 4a ), which work synergistically in vivo, to provide a maximal response to RA 25, 26 . We assessed the RARα occupancy of these promoter regions in ChIP experiments performed at 5 min intervals, up to 1 h, after RA addition to MEF(RARαWT). The specificity of our experimental conditions was checked in the absence of antibodies and with the promoter of the control 36B4 gene, which does not contain any RARE.
The proximal promoter region of Cyp26A1, which encompasses the DR5 R1, the TATA box and the transcription start site, was already occupied to some extent by RARα in the absence of RA (Table 1) . Then the level of DR5 R1 bound to RARα started to increase at 30 min after RA addition ( It is interesting to note that the corepressor SMRT was bound to R1 in the absence of RA, in line with the presence of RARα in this region, and dissociated rapidly after RA addition ( Fig. 4c ). However SMRT could not be detected at R2 consistent with the absence of RARα (Fig. 4b ).
As RARα binds TFIIH after RA addition, we also examined the recruitment of TFIIH in ChIP experiments performed with antibodies against its cyclin H, cdk7 or XPB subunits. In the absence of RA, the three TFIIH subunits already occupied R1, but could not be significantly detected at R2 (Table 1 and Fig. 4d ,e). In response to RA, the levels of R1 and R2 bound to TFIIH increased markeddly and reached a peak at 40-50 min ( regions of the CYP26A1 promoter was phosphorylated at S77 (Fig. 4f,g, lanes 6 ). Altogether, these results indicate that RARα bound at the promoter is associated with TFIIH and phosphorylated at S77. Note that RNA polII was also recruited to R1 and R2 in parallel to RARα and TFIIH (Fig. 4b,c) .
The phosphorylation cascade initiated at S369 and ending at S77 controls the recruitment of both RARα and TFIIH to the Cyp26A1 promoter.
Then we investigated whether phosphorylation is required for promoter recruitment of RARα, in ChIP experiments performed with MEF(RARαS369A) and MEF(RARαS77A) (Fig. 4h,i ). RARαS369A which does not interact with TFIIH and therefore cannot be phosphorylated at S77 in response to RA, was not recruited to R1 and R2. RARαS77A which has retained the ability to be phosphorylated at S369 and to interact with TFIIH was also not recruited. In both cases, TFIIH was not recruited either (Fig. 4j,k) . From these results and those above, one can conclude that the last step of the phosporylation cascade, i.e. S77
phosphorylation is required for the promoter recruitment of RARα-TFIIH complexes.
Activated MSK1 is also recruited to the Cyp26A1 promoter and phosphorylates Histones H3 at S10.
Next we investigated whether MSK1 is recruited to the Cyp26A1 promoter after RA addition and whether it phosphorylates histones H3 at S10 (H3S10p), a hallmark of gene 22/07/08 10 transcription activation 22 . ChIP assays performed with antibodies specific for phosphorylated MSK1 showed that, after RA addition to MEF(RARαWT), the activated kinase is recruited to the R1 and R2 regions (Fig. 5b,c) , concomitantly with RARα. H3 was phosphorylated at S10
in the same time slot as assessed in ChIPs with antibodies against H3S10p (Fig. 5b,c) .
Histones H4 were also acetylated at K5, K8 and K12 (Fig. 5b,c) . Note that in the context of the R1 region, an additional peak of H4 acetylation was observed at 20-25 min (Fig. 5c) ,
probably reflecting the recruitment of histone acetylases by RARα already bound to this region. Knockdown of MSK1 reduced significantly the accumulation of active MSK1 and H3S10 phosphorylation on both R1 and R2, (Fig. 5d,e) , confirming that the RA-induced phosphorylation of H3 is executed by MSK1 and suggesting an additional role for MSK1 in the activation of RARα-target promoters through histone phosphorylation. Interestingly it also blocked the recruitment of RARα and TFIIH (Fig. 5f,g ). Moreover, in SKBR3 cells which are defective in MSK1 activation compared to MCF7 cells, RARα and TFIIH recruitment to R2 and R1 remained low and unchanged, irrespective of the RA treatment duration (Fig. 5h,i ).
Phosphorylated RARα controls the formation of a bridge between the R1 and R2
regions of the Cyp26A1 promoter.
According to several recent studies, DNA looping may juxtapose promoter DNA with enhancer elements that lie far upstream 27 . Given that, in response to RA, RARα is recruited to both the R1 and R2 regions of the CYP26A1 promoter, in association with TFIIH and RNA PolII, we raised the hypothesis that RARα would bridge R1 and R2 to form an enhanceosome. To demonstrate the existence of such a gene looping, we performed ChIPloop assays 28 , which combine Chromosome Conformation Capture (3C) with chromatin immunoprecipitation (Fig. 6a) .
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In MEF(RARαWT) RA-treated for 50 min, PCR amplification of non digested immunoprecipitated material with primers corresponding to R1 and R2 (Fig. 6a2) , produced a 1930 bp fragment (Fig. 6b, lane 2) . Upon digestion with PvuII, which cuts twice between R1
and R2 (Fig. 6a4) , a new 1300 bp band was generated (Fig. 6b, lanes 8-15) , which represents loss of a 630 bp fragment and religation of the R1 and R2 regions that remained in close proximity due to bridging complexes. Religation was confirmed by PCR amplification with primers on both sides of the junction that generated a 360 bp fragment instead of a 1000 bp one (Fig.6b, lower panel) . The 1300 and 360 bp fragments were detected at 30 min up to 60-75 min following RA addition (Fig. 6b,c) , when RARα was recruited to both R1 and R2 in ChIP experiments (Fig. 4) . Similar results were obtained when immunoprecipitation was performed with TFIIH or RNA polII antibodies (Fig.6c) . Collectively, these results indicate that the R1 and R2 regions become juxtaposed in response to RA, through the recruitment of complexes involving RARα as well as TFIIH and RNA PolII. (Fig. 7) . To our knowledge, this is the first report of a coordinated phosphorylation cascade induced by RA and coupled to promoter activation. It was unexpected and shed light on a new level of complexity in the fine-tuning of RARα-mediated transcription.
The mechanism of activation of p38MAPK/MSK1 is out of the topic of this report, but involves very likely a non-genomic activation event 30 , similar to that described for steroid receptors 22, 31 and requiring liganded RARα. One of the targets of MSK1 is RARα which becomes rapidly phosphorylated at S369 located in the LBD and we found that phosphorylation of this residue is critical for the recruitment of TFIIH and the subsequent phosphorylation of the NTD at S77 by cdk7. Given that S369 is located in close proximity of the cyclin H binding domain 24 , we propose that, in vivo, phosphorylation of this residue by MSK1 propagates a signal to the cyclin H binding surface, allowing the recruitment of CAK within TFIIH, in line with our previous in vitro results 32 . Ultimately, the consequence of the last step of this cascade, i.e. S77 phosphorylation, is to anchor RARα-TFIIH complexes to target promoters. Additional investigations are required to determine how S77 phosphorylation affects the binding of RARα to response elements. Interestingly, in the context of a promoter with two RAREs, a proximal and a more distal one, as exemplified with the Cyp26A1 promoter, phosphorylated RARα bridges both RAREs, in association with TFIIH and RNA PolII. Whether other chromatin remodeling and/or transcription factors are also involved to form an enhanceosome 27 awaits further studies.
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The other novelty of this study is that MSK1 is recruited to RARα-target promoters in the active phosphorylated form, leading to increased phosphorylation of S10 on H3. A similar mechanism was recently reported for the regulation of other nuclear receptor target genes 22 .
Then the question is how MSK1-mediated phosphorylation of H3 contributes to RARα-target genes induction. One possibility is that phosphorylated H3S10 is a chromatin mark accounting in cooperation with other histones modifications for the dissociation of repressive complexes and/or the recruitment of chromatin-remodelling complexes 22 . Finally, how MSK1 is recruited to RA-target promoters and whether MSK1 phosphorylates other relevant targets will require further investigations
An unexpected finding in this study is that RARα-TFIIH complexes started to be Nevertheless it raises the issue of a contribution of the p38MAPK/MSK1 pathway in RAinduced growth arrest 37 and its specific modulation might be a promising therapeutic strategy in the treatment of RA-resistant cancers. Given that the S369 phosphorylation site is shared by MSK1 and PKA, our data are also particularly attractive in terms of the synergy between RA and cAMP in the treatment of many leukemia cells 38 .
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METHODS
Materials
RA was from Sigma Aldrich Corporation (USA). The synthetic retinoid agonists and antagonists were as described 12 . Rabbit polyclonal antibodies against RARα, RPα(F), and mouse monoclonal antibodies recognizing cyclin H and RARα phosphorylated at S77 or S369
were previously described 23 ,24 ,32 . Monoclonal antibodies against RNA polII phosphorylated at S5 in the carboxy terminal repeat domain, cyclin H and acetylated Histones (H4K5;12 and H4K5;8;12) were produced by the IGBMC facility. Antibodies against MSK1 and β-actin 
Cell lines and immunoblotting.
Mouse embryo fibroblasts with all three RARs deleted, MEF (RARα,β,γ)
-/-, were as described 18 . RARα WT, S369A or S77A cDNAs sub cloned from the pSG5 constructs 32 into pMSCV Neo plasmid, were reintroduced into these cells by retroviral transfer followed by G418 selection. MCF7
and SKBR3 human breast cancer cells were cultured under standard conditions. All cell lines were treated with RA (10 -7 M) after 24 hr in medium containing 1% dextran-charcoal-treated FCS.
Extracts were prepared and immunoblotted as described 39 .
RNA isolation and quantitative RT-PCR (qRT-PCR).
Total RNAs were isolated and subjected to qRT-PCR as described 39 Primers amplification specificity and efficiency were verified on DNA serial dilutions.
Occupancy of the promoters was calculated by normalizing the PCR signals from the IP samples to the signals obtained from the input DNA.
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For ChIP-Wersten experiments, the precipitated chromatin complexes were proceeded as described 41 and bound proteins were revealed by immunoblotting.
ChIP loop assay
Cells cross-linked with formaldehyde were digested with PvuII (New England Biolabs) (600 U, overnight, 37°C), religated (4 h at 16°C using T4 DNA ligase) as described in 27 and immunoprecipitated with RARα, TFIIH (XPB subunit) or RNA PolII antibodies. Ligation frequencies of restriction fragments were analyzed by qPCR with the following primer pairs. 
In vitro RARα phosphorylation and detection of Phosphorylated RARα and p38MAPK.
In vitro phosphorylation of purified recombinant RARα expressed in E. coli by the purified CAK complex 24 or recombinant active MSK1 (Upstate Biotechnology Incorporated, Lake Placid, NY, USA) was performed as previously described 11 followed by immunoblotting with antibodies recognizing RARα or RARα phosphorylated at S77 or S369.
For detection of in vivo phosphorylated RARα, cell extracts were prepared and applied to Phosphoprotein Affinity purification columns (PhosphoProtein Purification System, Qiagen S.A.) according to manufacturer-supplied instructions. After washing, column eluates containing protein peaks were concentrated and analyzed by immunoblotting. Phosphorylated 
